Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia
Public ClinicalTrials.gov record NCT05299554. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Open-Label Extension Study to Evaluate the Long-term Safety and Tolerability of Chronocort in the Treatment of Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase III study is an open-label extension study to be conducted at approximately 21 investigational sites across 3 countries. The study will evaluate the long-term safety and tolerability of Chronocort in participants aged 16 years and over when used as treatment for Congenital Adrenal Hyperplasia (CAH).
Study identification
- NCT ID
- NCT05299554
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 76 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2022
- Primary completion
- Jan 14, 2026
- Completion
- Jan 14, 2026
- Last update posted
- Jun 17, 2026
2022 – 2026
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Neurocrine Investigational Site in California | Los Angeles | California | 90027 | — |
| Neurocrine Investigational Site in California | Orange | California | 92868 | — |
| Neurocrine Investigational Site in Florida | Jacksonville | Florida | 32207 | — |
| Neurocrine Investigational Site in Iowa | Iowa City | Iowa | 52242 | — |
| National Institutes of Health Center | Bethesda | Maryland | 20892-1932 | — |
| Neurocrine Investigational Site in Michigan | Ann Arbor | Michigan | 48114 | — |
| Neurocrine Investigational Site in Minnesota | Rochester | Minnesota | 55901 | — |
| Neurocrine Investigational Site in Nevada | Las Vegas | Nevada | 89148 | — |
| Neurocrine Investigational Site in Texas | Dallas | Texas | 75235 | — |
| Neurocrine Investigational Site in Washington | Seattle | Washington | 98105 | — |
| Neurocrine Investigational Site in Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05299554, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 17, 2026 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05299554 live on ClinicalTrials.gov.